Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.

摘要: 513 Background: Pre-treatment BMI has been found to impact early breast cancer (EBC) outcomes and observational studies suggest that increasing after diagnosis is detrimental. We hypothesize changes in initial treatment of EBC are associated with outcomes. Methods: determined the effects on disease a series NCIC CTG clinical trials employing investigational therapies: chemotherapy (MA.5, MA.21), endocrine therapy (MA.12, MA.27), or biological such as insulin-like growth factor pathway (MA.14) trastuzumab (MA24/HERA). Taking into account differing trial designs we created common operable definitions for investigative factors (BMI change at 1-, 3-, 5- years; age; ECOG performance status; menopausal race; T; nodal hormone receptor therapy; chemotherapy; anthracycline; trastuzumab) STEEP endpoints. MA.14 MA.27 results provided here ...